- Home
- CLPS vs NRXP Comparison
CLPS vs NRXP Comparison
Compare CLPS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPS
- NRXP
- Stock Information
- Founded
- CLPS 2005
- NRXP 2015
- Country
- CLPS Hong Kong
- NRXP United States
- Employees
- CLPS N/A
- NRXP N/A
- Industry
- CLPS Computer Software: Prepackaged Software
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CLPS Technology
- NRXP Health Care
- Exchange
- CLPS Nasdaq
- NRXP Nasdaq
- Market Cap
- CLPS 26.0M
- NRXP 32.6M
- IPO Year
- CLPS 2018
- NRXP N/A
- Fundamental
- Price
- CLPS $0.93
- NRXP $3.34
- Analyst Decision
- CLPS
- NRXP Strong Buy
- Analyst Count
- CLPS 0
- NRXP 4
- Target Price
- CLPS N/A
- NRXP $28.50
- AVG Volume (30 Days)
- CLPS 10.9K
- NRXP 240.0K
- Earning Date
- CLPS 03-05-2025
- NRXP 08-13-2025
- Dividend Yield
- CLPS 14.20%
- NRXP N/A
- EPS Growth
- CLPS N/A
- NRXP N/A
- EPS
- CLPS N/A
- NRXP N/A
- Revenue
- CLPS $153,816,045.00
- NRXP N/A
- Revenue This Year
- CLPS N/A
- NRXP N/A
- Revenue Next Year
- CLPS N/A
- NRXP N/A
- P/E Ratio
- CLPS N/A
- NRXP N/A
- Revenue Growth
- CLPS 5.81
- NRXP N/A
- 52 Week Low
- CLPS $0.68
- NRXP $1.10
- 52 Week High
- CLPS $1.70
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CLPS 45.80
- NRXP 60.08
- Support Level
- CLPS $0.90
- NRXP $2.90
- Resistance Level
- CLPS $0.94
- NRXP $3.53
- Average True Range (ATR)
- CLPS 0.04
- NRXP 0.19
- MACD
- CLPS -0.00
- NRXP -0.03
- Stochastic Oscillator
- CLPS 39.56
- NRXP 84.13
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.